Phytochemicals intended for anticancer effects at preclinical levels to clinical practice: Assessment of formulations at nanoscale for non-small cell lung cancer (NSCLC …
THP Nguyen, VB Kumar, VK Ponnusamy, TTT Mai… - Process …, 2021 - Elsevier
Over the past few decades, many of the phytochemicals have been shown to possess
extraordinary anticancer effects, clinical tested, approved as drugs, and currently in use. A …
extraordinary anticancer effects, clinical tested, approved as drugs, and currently in use. A …
Single-arm oncology trials and the nature of external controls arms
M Hashmi, J Rassen… - Journal of Comparative …, 2021 - becarispublishing.com
Aim: Single-arm trials with external control arms (ECAs) have gained popularity in oncology.
ECAs may consist of primary data from previous trials, electronic health records (EHRs) or …
ECAs may consist of primary data from previous trials, electronic health records (EHRs) or …
[HTML][HTML] Plasma heat shock protein 90 alpha: A valuable predictor of early chemotherapy effectiveness in advanced non-small-cell lung cancer
B Zhong, J Shen, C Zhang, G Zhou, Y Yu… - … Medical Journal of …, 2021 - ncbi.nlm.nih.gov
Background Heat shock protein-90 alpha (HSP90α) is more abundant in non-small-cell lung
cancer (NSCLC) patients than in control individuals. However, whether it can reflect …
cancer (NSCLC) patients than in control individuals. However, whether it can reflect …
[HTML][HTML] Thyroid transcription factor 1 and p63 expression is associated with survival outcome in patients with non‑small cell lung cancer treated with erlotinib
M Svaton, O Fiala, G Krakorova… - Oncology …, 2020 - spandidos-publications.com
While erlotinib is primarily administered to patients with non‑small cell lung cancer with
sensitizing epidermal growth factor receptor (EGFR) mutations, it is also prescribed to …
sensitizing epidermal growth factor receptor (EGFR) mutations, it is also prescribed to …
[HTML][HTML] Second and later-line erlotinib use in non-small cell lung cancer: real world outcomes and practice patterns overtime in Canada
K Perdrizet, R Sutradhar, Q Li, N Liu… - Journal of Thoracic …, 2021 - ncbi.nlm.nih.gov
Background In Canada, epidermal growth factor receptor (EGFR) inhibitor therapies in
advanced non-small cell lung cancer (NSCLC) were initially approved regardless of EGFR …
advanced non-small cell lung cancer (NSCLC) were initially approved regardless of EGFR …
[PDF][PDF] Vliv klinických parametrů na výsledky léčby erlotinibem ve 2. a 3. linii léčby pacientů bez prokázané EGFR mutace s pokročilým NSCLC
M Svaton, L Jakubikova, M Hrnciarik… - Studia pneumol. et …, 2019 - plicnilekarstvi.cz
SOUHRN Úvod: Léčba erlotinibem u pacientů bez EGFR senzitivních mutací ve vyšších
liniích léčby nemalobuněčného plicního karcinomu (NSCLC) je úspěšná pouze u minoritní …
liniích léčby nemalobuněčného plicního karcinomu (NSCLC) je úspěšná pouze u minoritní …
Effects of Aquaporins1, ENAC Induced by Pro-b Cell Clonal Enhancer Factor on Growth, and Expression in Hypoxia/Reoxygenation Treated Human Non-Small Cell …
M You, Z Zhang, W Xu, C Lu, Y Gong… - Journal of Biomaterials …, 2019 - ingentaconnect.com
Objective: Lung cancer (LC) remains to be the most frequent cancer among male patients,
nonsmall-cell lung cancer (NSCLC) is the most common type of LC. Here we aim to …
nonsmall-cell lung cancer (NSCLC) is the most common type of LC. Here we aim to …
[引用][C] Efficacy and safety analysis of apatinib in the real-world treatment of metastatic gastric cancer
Z Jianhong, C Haihui, H Haixin, C Shaojun, L Wenping…